成纤维细胞生长因子5的研究进展 *

成纤维细胞生长因子5(fibroblast growth factor 5,FGF5)是成纤维细胞生长因子家族(FGFs)的成员之一,在哺乳动物毛囊,神经系统,睾丸等多个部位及胚胎发育过程中均有表达.研究发现,FGF5具有广泛的生物学活性,如作为毛发生长重要的调节因子其编码基因突变将导致毛发异常生长,作为丝裂原在干细胞增殖,血管生成和肢体肌发育等方面发挥重要作用,以及在高血压,肿瘤等方面具有重要的生物学功能.目前,FGF5在多种疾病中的功能和作用机制尚需进一步深入研究,但其在毛发生长,干细胞增殖及在心血管疾病等方面的生物学作用具有重大的意义和临床应用价值.总结了近些年FGF5的研究进展,系统阐述了FGF5在毛发生长,干细胞增殖分化,心血管疾病及癌症等方面的相关作用机制,为进一步深入研究FGF5在疾病治疗中的作用和开发利用提供参考.     

成纤维细胞生长因子5的研究进展

成纤维细胞生长因子5 (fibroblast growth factor 5,FGF5)是成纤维细胞生长因子家族(FGFs)的成员之一,在哺乳动物毛囊、神经系统、睾丸等多个部位及胚胎发育过程中均有表达。研究发现,FGF5具有广泛的生物学活性,如作为毛发生长重要的调节因子其编码基因突变将导致毛发异常生长,作为丝裂原在干细胞增殖、血管生成和肢体肌发育等方面发挥重要作用,以及在高血压、肿瘤等方面具有重要的生物学功能。目前,FGF5在多种疾病中的功能和作用机制尚需进一步深入研究,但其在毛发生长、干细胞增殖及在心血管疾病等方面的生物学作用具有重大的意义和临床应用价值。总结了近些年FGF5的研究进展,系统阐述了FGF5在毛发生长、干细胞增殖分化、心血管疾病及癌症等方面的相关作用机制,为进一步深入研究FGF5在疾病治疗中的作用和开发利用提供参考。     

成纤维细胞生长因子18(FGF18)的研究进展

成纤维细胞生长因子18 (fibroblast growth factor 18,FGF18)是成纤维细胞生长因子家族( FGFs)的成员之一.研究发现,FGF 18不仅在骨骼发育和生长期对软骨形成和成骨生成起着重要的作用,其功能也已延伸至其他许多生物过程,尽管对FGF18作为一个有用治疗靶点发挥作用的功能和机制仍有待进一步的发现及研究.现针对FGF18的特点,及其在骨骼发育中的功能,特别其在未来具有潜在应用领域上的研究进展进行综述.     

碱性成纤维细胞生长因子促进神经损伤修复的研究进展

碱性成纤维细胞生长因子(basic fibroblast growth factor,b FGF)是成纤维细胞生长因子家族(FGFs)的成员之一。它是哺乳动物和人体中一种非常微量的活性物质,因其具有广泛的生理功能和重要的临床应用价值受到了国内外学者的高度重视。b FGF生物活性的多效性以及神经营养的广谱性,为其从基础走向临床提供了保证。而b FGF如何发挥神经损伤修复作用的功能和机制,仍有待进一步的发现及研究,这也是目前国内外探索和开发b FGF新临床药物的研究热点之一。针对b FGF的生物学特点及其在神经损伤修复中的功能,特别是在中枢神经系统和外周神经系统疾病中的研究进展进行了综述。     

FGF9与FGFR3受体在骨发育与疾病中的作用

成纤维细胞生长因子9(fibroblast growth factor,FGF9)最初发现于人类神经胶质瘤细胞,是成纤维细胞生长因子家族的成员之一.研究发现FGF9在多种组织的发育及疾病的发生中起重要作用.FGF9与肝素结合活化FGFR3受体,可作用于软骨细胞,在骨骼发育及损伤过程中抑制软骨细胞增生和软骨内骨化.FGF9基因缺失或突变可分别导致骨骼发育不良或肿瘤.本文简要综述FGF9与FGFR3受体在骨发育中的作用及其致病机制的研究进展.     

骨源性激素样蛋白FGF23对骨外器官的代谢调控

成纤维细胞生长因子23(fibroblast growth factor 23,FGF23)由骨骼中的成骨细胞和骨细胞分泌,作为激素样蛋白在复杂的内分泌网络中发挥核心作用,是调节细胞外基质矿化的局部骨源因子和参与矿物代谢的全身激素.FGF23主要靶向肾脏调节磷酸盐的重吸收,1,25--二羟基维生素D的产生和分解代谢以及...     

成纤维细胞生长因子信号在骨损伤修复中的作用

骨损伤是常见的骨外科疾病。许多复杂的骨缺损,如创伤性大块骨缺损等常导致骨折延迟愈合及骨不连,是临床治疗中的难题。组织工程方法的运用为骨不连等的治疗提供了新的契机。成纤维细胞生长因子(fibroblast growth factor, FGF)信号在骨骼发育过程中发挥重要作用。基于其家族成员在骨折愈合过程中的时空表达及相关基因工程小鼠的表型,FGF信号相关分子被认为是骨再生修复的重要调节分子。该文将对FGF信号在骨损伤修复中的作用及应用方面的研究进展做综述,以期为其临床应用提供借鉴与参考。     

成纤维细胞生长因子8(FGF8)研究进展

成纤维细胞生长因子8(fibroblast growth factor 8,FGF8)是成纤维细胞生长因子(FGFs)家族的成员之一。其在人胚胎时期多种组织内进行表达,对各种器官的形成中起着重要的作用。在正常成人体内,FGF8的表达水平受到严格的限制,然而在某些癌细胞或炎症部位中大量表达,特别是在激素类癌症的发生和发展中起着重要的作用。因此应用FGF8抗体治疗激素类癌症,为临床提供了新的治疗途径。     

成纤维细胞生长因子22(FGF22)的研究进展

成纤维细胞生长因子22(fibroblast growth factor 22)是成纤维细胞生长因子家族(FGFs)的成员之一。研究发现,FGF22主要在大脑和皮肤中表达并且能够影响大脑发育和神经突触的形成。由于FGF22在难治性癫痫发生机制中所发挥的特殊作用,有可能作为研究癫痫疾病的新的切入点。此外FGF22与脊髓损伤修复、神经系统疾病、皮肤癌、抑郁等疾病有着重要的联系。特别是在神经突出的形成过程中FGF22起着调节因子的作用。尽管作为重组蛋白药物的开发其功能和机制仍有待进一步研究,但相信FGF22所具备的生物学特性具有非常广阔的研究领域和应用价值。     

FGF23/α-Klotho信号传导的分子机制

成纤维细胞生长因子23(fibroblast growth factor 23,FGF23)是内分泌型FGFs家族中的重要一员,是一种重要的骨源性调磷激素。FGF23主要通过结合成纤维细胞生长因子受体(fibroblast growth factor receptor,FGFRs)/α-Klotho的复合物来调控肾脏中磷和维生素D的代谢。FGF23信号通路的异常与多种代谢性疾病尤其是慢性肾病(chronic kidney disease,CKD)有非常密切的关系。FGF23水平的不断上升是导致CKD患者疾病进程加快、诱发并发症甚至最终死亡的主要因素。通过对最近发表的FGF23-FGFR1c-α-Klotho三元复合物蛋白结构的分析,更好地阐明FGF23蛋白信号传导的分子机制,为相关疾病的治疗或药物开发提供新的策略。     

Model analysis of difference between EGF pathway and FGF pathway

The difference in time course of Ras and mitogen activated protein kinase (MAPK) cascade by different growth factors is considered to be the cause of different cellular responses. We have developed the computer simulation of Ras-MAPK signal transduction pathway containing newly identified negative feedback system, Sprouty, and adaptor molecules. Unexpectedly, negative feedback system did not profoundly affect time course of MAPK activation. We propose the key role of fibroblast growth factor receptor substrate 2 (FRS2) in NGF/FGF pathway for sustained MAPK activation. More Grb2-SOS complexes were recruited to the plasma membrane by binding to membrane-bound FRS2 in FGF pathway than in EGF pathway and caused sustained activation of ERK. The EGF pathway with high concentration of EGF receptor also induced sustained MAPK activation, which is consistent with the results in the PC12 cell overexpressing the EGF receptors. The simulated time courses of FRS2 knock-out cells were consistent with those of the reported experimental results.     

Expression of fibroblast growth factor receptor 3 by fibroblast growth factor 2 in cultured chick embryo chondrocytes

Although fibroblast growth factor 2 (FGF2) and fibroblast growth factor receptor 3 (FGFR3) both inhibit longitudinal bone growth, little is known about the relationship between FGF2 and FGFR3. Accordingly, the current study examined the expression of FGFR3 mRNA after the administration of FGF2 using cultured chondrocytes from day 17 chick embryos to evaluate the relationship between FGF2 and FGFR3. The chondrocytes were isolated from the caudal one-third portion (LS) of sterna, peripheral regions (USP) and central core regions (USC) of the cephalic portion of the sterna, and lower portion of the proximal tibial growth plate (Ti) of day 17 chick embryo. The expression of FGFR1, FGFR3, and type II and X collagen mRNA in the chondrocytes from the LS, USP, USC, and Ti was determined. FGFR1 was not expressed in the LS and USP chondrocytes, yet strongly expressed in the USC and Ti chondrocytes. With a treatment of FGF2, the expression of FGFR1 slightly increased in the USC chondrocytes and was not related with the concentration of FGF2 in the Ti chondrocytes. FGFR3 was expressed in all the chondrocyte types, yet strongly increased in the LS, USC, USP, and Ti in that order according to the concentration of FGF2. For the LS and USP chondrocytes, the expression of FGFR3 with FGF2 increased in a 4-day culture, yet decreased in a 6-day culture, whereas for the USC chondrocytes, the expression of FGFR3 mRNA with FGF2 increased in a 2-day culture, yet decreased in a 4-day culture, suggesting that the hypertrophic chondrocytes were more numerous and sensitive compared to the proliferative chondrocytes. For all the chondrocyte types, FGF2 appeared to be up-regulated to FGFR3, as the expression of FGFR3 mRNA increased with a higher concentration of FGF2 until a peak level. In conclusion, FGF2 was found to up-regulate to FGFR3 until the peak level of FGFR3 mRNA expression, while in hypertrophic chondrocytes, FGFR3 appeared to cause the differentiaton of chondrocytes, resulting in the inhibition of longitudinal bone growth after the peak level of FGFR3 mRNA expression.     

Skeletal FGFR1 signaling is necessary for regulation of serum phosphate level by FGF23 and normal life span

Fibroblast growth factor (FGF) 23 produced by the bone is the principal hormone to regulate serum phosphate level. Serum FGF23 needs to be tightly regulated to maintain serum phosphate in a narrow range. Thus, we hypothesized that the bone has some phosphate-sensing mechanism to regulate the production of FGF23. Previously we showed that extracellular phosphate induces the phosphorylation of FGF receptor 1 (FGFR1) and FGFR1 signaling regulates the expression of Galnt3, whose product works to increase FGF23 production in vitro. In this study, we show the significance of FGFR1 in the regulated FGF23 production and serum phosphate level in vivo. We generated late-osteoblast/osteocyte-specific Fgfr1-knockout mice (Fgfr1^fl/fl; Ocn^Cre/+) by crossing the Ocn-Cre and the floxed Fgfr1 mouse lines. We evaluated serum phosphate and FGF23 levels, the expression of Galnt3 in the bone, the body weight and life span. A selective ablation of Fgfr1 aborted the increase of serum active full-length FGF23 and the enhanced expression of Galnt3 in the bone by a high phosphate diet. These mice showed more pronounced hyperphosphatemia compared with control mice. In addition, these mice fed with a control diet showed body weight loss after 23 weeks of age and shorter life span. These results reveal a novel significance of FGFR1 signaling in the phosphate metabolism and normal life span.     

Expression of the fetal-oncogenic fibroblast growth factor-8/17/18 subfamily in human hematopoietic tumors

The fibroblast growth factors (FGFs) are involved in hematopoiesis and tumorigenesis. However, little is known about the contribution of the FGFs identified within the past 10 years to leukemogenesis. To elucidate whether these FGFs (FGF-8, -9, -10, -11, -12, -13, -14, -16, -17, -18, -19, -20, and -21) are expressed in leukemic cells, we performed RT-PCR analyses using 28 cell lines. The members of a fetal-oncogenic subfamily, FGF-8/-17/-18, were often expressed (53.5%, 25.0%, and 32.1%) with the co-expression of their receptors. Realtime quantitative-PCR analysis showed that FGF-8/-17 were aberrantly expressed in patients with acute leukemia. Moreover, cell proliferation assays revealed the proliferation activity of FGF-17 on leukemic cells expressing its receptors. These results demonstrated that certain recently identified FGFs play an important role in the growth of leukemic cells, possibly with an autocrine mode of action, and that these FGFs will become novel biomarkers for hematopoietic tumors.     

人神经干细胞的体外生物学特性

本实验利用有丝分裂因子,体外诱导生成人神 经干细胞(NSCs),观察其生长特性并进行鉴定。取胎龄10-22周的大脑半球,分散细胞后种于添加表皮生长因子(EGF,20ng/ml)和/或碱性成纤维生长因子(bFGF,20ng/ml)的培养基中。利用免疫组织化学方法鉴定分化后的细胞类型。同时,进行细胞克隆分析、传代培养及端粒酶活性检测。结果显示:NSCs呈悬浮生长的干细胞球,其特异性抗原nestin阳性。NSCs具有增殖能力,可连续传代而不丢失其增殖和多分化潜能的干细胞特性。撤除EGF和bFGF的作用,细胞停止分裂,并分化为神经元、星形胶质细胞和少突胶质细胞。克隆分析显示NSCs生长呈密度依赖性。人NSCs表达较低的端粒酶水平,并随培养时间延长而下调。研究表明,利用有丝分裂因子,可在体外成功诱导生成人NSCs,其生长,分化受内外源因素的调节,相关的机制还有待阐明。     

噬菌体展示技术筛选bFGF模拟短肽

目的：通过噬菌体展示技术筛选得到与FGFR结合的bFGF模拟短肽,为bFGF肽类抑制剂的研发提供实验基础。方法：以Balb/c 3T3细胞为靶标,以COS-7细胞作消减,对噬菌体随机七肽库进行4轮生物淘洗,再采用ELISA检测单克隆噬菌体对Balb/c 3T3亲和性和特异性,选取阳性克隆进行DNA测序分析。结果：从富集的噬菌体中获得12个阳性克隆,获得一组疏水性七肽及共同基序PR。结论：利用肽类新药开发的重要工具--噬菌体展示技术,得到2段bFGF的受体结合模拟肽,可望作为bFGF抑制剂的先导肽。     

FGFR signalling in women's cancers

FGFs, in a complex with their receptors (FGFRs) and heparan sulfate (HS), are responsible for a range of cellular functions, from embryogenesis to metabolism. Both germ line and somatic FGFR mutations are known to play a role in a range of diseases, most notably craniosynestosis dysplasias, dwarfism and cancer. Because of the ability of FGFR signalling to induce cell proliferation, migration and survival, FGFRs are readily co-opted by cancer cells. Mutations in, and amplifications of, these receptors are found in a range of cancers with some of the most striking clinical findings relating to their contribution to pathogenesis and progression of female cancers. Here, we outline the molecular mechanisms of FGFR signalling and discuss the role of this pathway in women's cancers, focusing on breast, endometrial, ovarian and cervical carcinomas, and their associated preclinical and clinical data. We also address the rationale for therapeutic intervention and the need for FGFR-targeted therapy to selectively target cancer cells in view of the fundamental roles of FGF signalling in normal physiology.     

pp42/44MAP Kinase Is a Component of the Neurogenic Pathway Utilized by Nerve Growth Factor in PC12 Cells

Nerve growth factor-stimulated mitogen-activated protein kinase (pp42/44MAP) kinase was characterized by sequential column chromatography on DEAE-Sephacel, phenyl-Sepharose CL4B, and S-200. The kinase displayed an apparent molecular mass of 42 kDa and reacted with an antiphosphotyrosine antibody. Peptide mapping of myelin basic protein revealed the presence of one phosphopeptide that was phosphorylated on Thr-97. pp42/44MAP kinase activity was dependent on Mg2+ and inhibited by K252a both in vitro and in vivo. Nerve growth factor-stimulated kinase activation was diminished by down-regulation of protein kinase C with 200 nM 12-phorbol 13-myristate acetate or with staurosporine (1 nM), a protein kinase C inhibitor. Genistein, a protein tyrosine kinase inhibitor, blocked nerve growth factor-mediated neurite extension as well as diminished activation of pp42/44MAP kinase. Our data demonstrate that activation of this kinase system by nerve growth factor displays a requirement for both protein kinase C as well as protein tyrosine kinase. In addition, other agents that are capable of promoting neurite outgrowth in PC12 cells, such as fibroblast growth factor or dibutyryl cyclic AMP, do so independently of activating this kinase system.     

Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping

Introduction of a Michael acceptor on a flexible scaffold derived from pan-FGFR inhibitors has successfully yielded a novel series of highly potent FGFR4 inhibitors with selectivity over FGFR1. Due to reduced lipophilicity and aromatic ring count, this series demonstrated improved solubility and permeability. However, plasma instability and fast metabolism limited its potential for in vivo studies. Efforts have been made to address these problems, which led to the discovery of compound (?)-11 with improved stability, CYP inhibition, and good activity/selectivity for further optimization.     

Nerve Growth Factor Stimulates the Production of Inositol 1,3,4-and 1,4,5-Trisphosphate and Inositol 1,3,4,5-Tetrakisphosphate in PC 12 Cells

Abstract: In PC12 cells, preincubated with [³H]inositol, nerve growth factor (NGF) stimulated an ～ 100% increase in the levels of [³H]inositol 1,3,4-trisphosphate {[³H]-Ins(1,3,4)P₃}, [³H]inositol 1,4,5-trisphosphate {[³H]lns(1,4,5)P₃}, and [³H]inositol 1,3,4,5-tetrakisphosphate {[³H]-Ins(1,3,4,5)P₄} as early as 5–15 s after addition of NGF. This NGF-mediated response was apparent only when the cells had been cultured in the absence of fetal bovine serum (FBS). PC12 cells cultured in FBS-containing medium did not display NGF-mediated increases in [³H]-Ins(1,3,4)P₃, [³H]-Ins(1,4,5)P₃, and [³H]-Ins(1,3,4,5)P₄ levels. Using cells cultured in the absence of FBS, epidermal growth factor (EGF) and fibroblast growth factor also stimulated production of [³H]lns(1,3,4)P₃, [³H]-Ins(1,4,5)P₃, and [³H]lns(1,3,4,5)P₄. Lavendustin A, a tyrosine kinase inhibitor, inhibited both the EGF-and NGF-stimulated increases in the levels of these tritiated inositol phosphates. These results suggest that NGF stimulates the production of lns(1,3,4)P₃, lns(1,4,5)P₃, and lns(1,3,4,5)P₄ and that this response is dependent on tyrosine kinase activity. Furthermore, although the production of lns(1,3,4)P₃, lns(1,4,5)P₃, and lns(1,3,4,5)P₄ may be a common response to factors stimulating neuronal differentiation, it is not sufficient for stimulation of neuronal differentiation.